Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis

American Journal of Nephrology

Volumn 43, Issue 4, 2016, Pages 229-236

  Dias, Clapton ^a   Moore, Kenneth Todd ^a   Murphy, Joe ^a   Ariyawansa, Jay ^a   Smith, William ^b   Mills, Roger M ^a   Weir, Matthew R ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulant ? Factor Xa inhibitor ? Rivaroxaban ? End stage renal disease ? Hemodialysis ? Pharmacokinetics ? Pharmacodynamics

Indexed keywords

CREATININE; HEPARIN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; GINGIVITIS; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTHROMBIN TIME; SINGLE DRUG DOSE; THROMBOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ADULT; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; METABOLISM; MIDDLE AGED;

ADULT; CASE-CONTROL STUDIES; FACTOR XA INHIBITORS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RIVAROXABAN;

EID: 84964239514     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000445328     Document Type: Article

References (9)

1. Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 2013; 11: 10.
2. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53: 1-16.
3. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
4. XARELTO ® (rivaroxaban) tablets, for oral use [package insert] Titusville, Janssen Pharmaceuticals, Inc. 2015.
5. Rohde G. Determination of rivaroxaban-A novel, oral, direct factor Xa inhibitor-in human plasma by high-performance liquid chromatography-Tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50.
6. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, Lufft V, Wand DD, Philipp T, Bruck H. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010; 70: 703-712.
7. Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004; 66: 2446-2453.
8. Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2015, Epub ahead of print
9. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries KH, Tu JV, Behlouli H, Guo H, Pilote L. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014; 129: 1196-1203.